AR122300A1 - Formulaciones proliposomales de testosterona undecanoato - Google Patents

Formulaciones proliposomales de testosterona undecanoato

Info

Publication number
AR122300A1
AR122300A1 ARP200102272A ARP200102272A AR122300A1 AR 122300 A1 AR122300 A1 AR 122300A1 AR P200102272 A ARP200102272 A AR P200102272A AR P200102272 A ARP200102272 A AR P200102272A AR 122300 A1 AR122300 A1 AR 122300A1
Authority
AR
Argentina
Prior art keywords
weight
testosterone undecanoate
ratio
proliposomal
proliposomal powder
Prior art date
Application number
ARP200102272A
Other languages
English (en)
Inventor
Veeran Gowda Kadajji
Natarajan Venkatesan
Nitin K Swarnakar
Teresa Hong
Ramachandran Thirucote
Guru V Betageri
Original Assignee
Tesorxpharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesorxpharma Llc filed Critical Tesorxpharma Llc
Publication of AR122300A1 publication Critical patent/AR122300A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a dispersiones de polvo proliposomales de testosterona undecanoato (TU) y fosfolípidos, que incluye dispersiones de TU y palmitoilfosfatidilcolina (DPPC), donde la relación peso/peso (p/p) de TU:DPPC en la dispersión de polvo proliposomal es aproximadamente 1:2; o TU y 1,2-dimiristoil-sn-glicero-3-fosfocolina (DMPC), donde la relación peso/peso (p/p) de TU:DMPC en la dispersión de polvo proliposomal es aproximadamente 1:3; o TU y 1-miristoil-2-palmitoil-sn-glicero 3-fosfocolina (MPPC), donde la relación peso/peso (p/p) de TU:MPPC en la dispersión de polvo proliposomal es aproximadamente 1:3.
ARP200102272A 2019-08-09 2020-08-10 Formulaciones proliposomales de testosterona undecanoato AR122300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962884919P 2019-08-09 2019-08-09

Publications (1)

Publication Number Publication Date
AR122300A1 true AR122300A1 (es) 2022-08-31

Family

ID=74569809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102272A AR122300A1 (es) 2019-08-09 2020-08-10 Formulaciones proliposomales de testosterona undecanoato

Country Status (13)

Country Link
US (1) US20220265679A1 (es)
EP (1) EP4009950A4 (es)
JP (1) JP2022544197A (es)
KR (1) KR20220054318A (es)
CN (1) CN114667133A (es)
AR (1) AR122300A1 (es)
AU (1) AU2020329775A1 (es)
BR (1) BR112022002418A2 (es)
CA (1) CA3146515A1 (es)
IL (1) IL290464A (es)
MX (1) MX2022001417A (es)
TW (1) TW202216162A (es)
WO (1) WO2021030260A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
EA201791738A1 (ru) * 2012-05-09 2018-03-30 Вестерн Юниверсити Оф Хелт Сайенсиз Пролипосомальные композиции тестостерона
JP2019501199A (ja) * 2016-01-08 2019-01-17 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ プロリポソームテストステロンウンデカノエート製剤

Also Published As

Publication number Publication date
EP4009950A4 (en) 2023-07-05
CA3146515A1 (en) 2021-02-18
JP2022544197A (ja) 2022-10-17
BR112022002418A2 (pt) 2022-06-14
TW202216162A (zh) 2022-05-01
EP4009950A1 (en) 2022-06-15
CN114667133A (zh) 2022-06-24
WO2021030260A1 (en) 2021-02-18
KR20220054318A (ko) 2022-05-02
MX2022001417A (es) 2022-06-08
IL290464A (en) 2022-04-01
US20220265679A1 (en) 2022-08-25
AU2020329775A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
BR112018002109A2 (pt) composições e métodos para fornecer materiais fluorescentes
BR112016018283A2 (pt) Composição que compreende bifidobacterium animalis ssp. lactis
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
CO2020001242A2 (es) Dihidrooxadiazinonas
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
BR112022019614A2 (pt) Dispersões de poliuretano de base biológica para aplicações cosméticas decorativas
UY29417A1 (es) Agentes endoparasiticidas
CO2021000147A2 (es) Composición agrícola
AR122300A1 (es) Formulaciones proliposomales de testosterona undecanoato
BR112015022484A2 (pt) formulações com oxidação reduzida
BR112018069900A2 (pt) composição antimicrobiana, método de limpeza ou desinfecção de uma superfície e uso de um complexo fosfolipídico catiônico
AR118985A1 (es) Composición que comprende fibra y proteína
CL2019003763A1 (es) Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta.
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
BR112023024034A2 (pt) Polipeptídeos de sars-cov-2
BR112015022475A2 (pt) formulações com oxidação reduzida